Juan Pablo Frias (Juan Frias, Juan P Frias, Juan P Frías)

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 38

Top Topics

Randomized Controlled Trial

Cardiovascular Risk Factors

Top Venues

Diabetes, obesity & metabolism

Obesity (Silver Spring, Md.)

The New England journal of medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Thomas Forst, Christophe E M De Block, Stephano Del Prato, Sara Armani, Juan Pablo Frias, Anne Lautenbach, Bernhard Ludvik, Marina Marinez, Chantal Mathieu, Timo Dirk Müller, Oliver Schnell
The role of incretin receptor agonists in the treatment of obesity. Diabetes, obesity & metabolism (2024)
José Orlando Alemán, Jaime P Almandoz, Juan Pablo Frias, Rodolfo J Galindo
Obesity among Latinx people in the United States: A review. Obesity (Silver Spring, Md.) 31 (2) (2023)
José Orlando Alemán, Jaime P Almandoz, Juan Pablo Frias, Rodolfo J Galindo
Obesity among Latinx people in the United States: A review. Obesity (Silver Spring, Md.) 31 (2) (2023)
Stephen Caldwell, Arun J Sanyal, Kris V Kowdley, Deepak L Bhatt, Rohit L Loomba, Juan Pablo Frias, Pierre Bedossa, Stephen A Harrison, Donald Lazas, Robert Barish, Mildred D Gottwald, Shibao Feng, Germaine D Agollah, Cynthia L Hartsfield, Hank Mansbach, Maya Margalit, Manal F Abdelmalek
Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH. The New England journal of medicine (2023)
José Orlando Alemán, Jaime P Almandoz, Juan Pablo Frias, Rodolfo J Galindo
Obesity among Latinx people in the United States: A review. Obesity (Silver Spring, Md.) 31 (2) (2023)
José Orlando Alemán, Jaime P Almandoz, Juan Pablo Frias, Rodolfo J Galindo
Obesity among Latinx people in the United States: A review. Obesity (Silver Spring, Md.) 31 (2) (2023)
Ania M Jastreboff, Lee M Kaplan, Juan Pablo Frias, Qiwei Wu, Yu Du, Sirel Gurbuz, Tamer Coskun, Axel Haupt, Zvonko Milicevic, Mark L Hartman, null null
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. The New England journal of medicine (2023)
José Orlando Alemán, Jaime P Almandoz, Juan Pablo Frias, Rodolfo J Galindo
Obesity among Latinx people in the United States: A review. Obesity (Silver Spring, Md.) 31 (2) (2023)
Yuan-Di C Halvorsen, John Paul Lock, Juan Pablo Frias, Francisco José Tinahones, Dominik Dahl, Annie L Conery, Mason W Freeman
A 96-week, double-blind, randomized controlled trial comparing bexagliflozin to glimepiride as an adjunct to metformin for the treatment of type 2 diabetes in adults. Diabetes, obesity & metabolism (2022)
Juan Pablo Frias, JaeDuk Choi, Julio Rosenstock, Luiza Popescu, Elisabeth Niemoeller, Isabel Muehlen-Bartmer, SeungJae Baek
Efficacy and Safety of Once-Weekly Efpeglenatide Monotherapy Versus Placebo in Type 2 Diabetes: The AMPLITUDE-M Randomized Controlled Trial. Diabetes care 45 (7) (2022)
Leigh Perreault, Melanie Davies, Juan Pablo Frias, Peter Nørkjaer Laursen, Ildiko Lingvay, Sriram Machineni, Anette Varbo, John P H Wilding, Signe Olrik Rytter Wallenstein, Carel W le Roux
Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program. Diabetes care 45 (10) (2022)
Julio Rosenstock, Lawrence Blonde, Vanita R Aroda, Juan Pablo Frias, Elisabeth Souhami, Chen Ji, Elisabeth Niemoeller, Stephano Del Prato
Switching to iGlarLixi versus continuation of a daily or weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) in insufficiently controlled type 2 diabetes: A LixiLan-G trial subgroup analysis by HbA1c and GLP-1 RA use at screening. Diabetes, obesity & metabolism 23 (6) (2021)
Juan Pablo Frias, Enzo Bonora, Luis Nevarez Ruiz, Ying G Li, Zhuoxin Yu, Zvonko Milicevic, Raleigh Malik, M Angelyn Bethel, David A Cox
Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11). Diabetes care 44 (3) (2021)
Juan Pablo Frias, Melanie J Davies, Julio Rosenstock, Federico C Pérez Manghi, Laura Fernández Landó, Brandon K Bergman, Bing Liu, Xuewei Cui, Katelyn Brown, null null
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. The New England journal of medicine 385 (6) (2021)
Juan Pablo Frias, Enzo Bonora, David A Cox, M Angelyn Bethel, Anita Y M Kwan, Sohini Raha, Raleigh E Malik
Glycaemic efficacy of an expanded dose range of dulaglutide according to baseline glycated haemoglobin (HbA1c) subgroup: Post hoc analysis of AWARD-11. Diabetes, obesity & metabolism 23 (12) (2021)
Juan Pablo Frias, Jill Maaske, Lisa Suchower, Lars Johansson, Paul D Hockings, Nayyar Iqbal, John P H Wilding
Long-term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104-week extension to a 52-week randomized, phase 3 study and liver fat MRI substudy. Diabetes, obesity & metabolism 24 (1) (2021)
Juan Pablo Frias, Enzo Bonora, Luis Nevárez Ruiz, Stanley H Hsia, Heike Jung, Sohini Raha, David A Cox, M Angelyn Bethel, Manige Konig
Efficacy and safety of dulaglutide 3.0 and 4.5 mg in patients aged younger than 65 and 65 years or older: Post hoc analysis of the AWARD-11 trial. Diabetes, obesity & metabolism 23 (10) (2021)
Lawrence Blonde, Julio Rosenstock, Juan Pablo Frias, Andreas L Birkenfeld, Elisabeth Niemoeller, Elisabeth Souhami, Chen Ji, Stephano Del Prato, Vanita R Aroda
Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study. Diabetes care 44 (3) (2021)
Juan Pablo Frias, Guillermo Gonzalez-Galvez, Eva Johnsson, Jill Maaske, Marcia A Testa, Donald C Simonson, Nalina Dronamraju, Ricardo Garcia-Sanchez, Anne L Peters
Efficacy and safety of dual add-on therapy with dapagliflozin plus saxagliptin versus glimepiride in patients with poorly controlled type 2 diabetes on a stable dose of metformin: Results from a 52-week, randomized, active-controlled trial. Diabetes, obesity & metabolism 22 (7) (2020)
Thomas Danne, Steven Edelman, Juan Pablo Frias, Francisco Javier Ampudia-Blasco, Philip Banks, Wenjun Jiang, Michael J Davies, Sangeeta Sawhney
Efficacy and safety of adding sotagliflozin, a dual sodium-glucose co-transporter (SGLT)1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline body mass index ≥ 27 kg/m2. Diabetes, obesity & metabolism 23 (3) (2020)
Juan Pablo Frias, Michael A Nauck, Joanna Van, Charles Benson, Ross Bray, Xuewei Cui, Zvonko Milicevic, Shweta Urva, Axel Haupt, Deborah A Robins
Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens. Diabetes, obesity & metabolism 22 (6) (2020)
Stephano Del Prato, Juan Pablo Frias, Lawrence Blonde, Vanita R Aroda, Niam Shehadeh, Aramesh Saremi, Terry Dex, Elisabeth Niemoeller, Elisabeth Souhami, Minzhi Liu, Julio Rosenstock
Impact of disease duration and β-cell reserve on the efficacy of switching to iGlarLixi in adults with type 2 diabetes on glucagon-like peptide-1 receptor agonist therapy: Exploratory analyses from the LixiLan-G trial. Diabetes, obesity & metabolism 22 (9) (2020)
Serge A Jabbour, Juan Pablo Frias, Azazuddin Ahmed, Elise Hardy, Jasmine Choi, C David Sjöström, Cristian Guja
Efficacy and Safety Over 2 Years of Exenatide Plus Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial. Diabetes care 43 (10) (2020)
Thomas Blevins, Qianyi Zhang, Juan Pablo Frias, Hideaki Jinnouchi, Annette M Chang, null null
Randomized Double-Blind Clinical Trial Comparing Ultra Rapid Lispro With Lispro in a Basal-Bolus Regimen in Patients With Type 2 Diabetes: PRONTO-T2D. Diabetes care 43 (12) (2020)
Eleuterio Ferrannini, Simona Baldi, Juan Pablo Frias, Cristian Guja, Elise Hardy, Enrico Repetto, Serge A Jabbour, Muhammad Abdul-Ghani
Hormone-substrate changes with exenatide plus dapagliflozin versus each drug alone: The randomized, active-controlled DURATION-8 study. Diabetes, obesity & metabolism 22 (1) (2019)
Vanita R Aroda, Matthew S Capehorn, Louis Chaykin, Juan Pablo Frias, Nanna L Lausvig, Stanislava Macura, Jörg Lüdemann, Sten Madsbad, Julio Rosenstock, Omur Tabak, Sayeh Tadayon, Stephen C Bain
Impact of baseline characteristics and beta-cell function on the efficacy and safety of subcutaneous once-weekly semaglutide: A patient-level, pooled analysis of the SUSTAIN 1-5 trials. Diabetes, obesity & metabolism 22 (3) (2019)
Sean D Sullivan, Charlie J Nicholls, Rishab A Gupta, Arjun A Menon, Jasmanda Wu, Jukka Westerbacka, Zsolt Bosnyak, Juan Pablo Frias, Timothy S Bailey
Comparable glycaemic control and hypoglycaemia in adults with type 2 diabetes after initiating insulin glargine 300 units/mL or insulin degludec: The DELIVER Naïve D real-world study. Diabetes, obesity & metabolism 21 (9) (2019)
Lawrence Blonde, Julio Rosenstock, Stephano Del Prato, Robert R Henry, Naim Shehadeh, Juan Pablo Frias, Elisabeth Niemoeller, Elisabeth Souhami, Chen Ji, Vanita R Aroda
Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial. Diabetes care 42 (11) (2019)
Juan Pablo Frias, Zachary Zimmer, Raymond L H Lam, Guillermo Amorin, Catherine Ntabadde, Carol Iredale, Edward A O'Neill, Samuel S Engel, Keith D Kaufman, Hideo Makimura, Michael F Crutchlow
Double-blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin uptitration in the treatment of patients with type 2 diabetes: The CompoSIT-M study. Diabetes, obesity & metabolism 21 (5) (2019)
Juan Pablo Frias, Alan G Wynne, Beata Matyjaszek-Matuszek, Dagmar Bartaskova, David A Cox, Brad Woodward, Ying G Li, Lai S Tham, Zvonko Milicevic
Efficacy and safety of an expanded dulaglutide dose range: A phase 2, placebo-controlled trial in patients with type 2 diabetes using metformin. Diabetes, obesity & metabolism 21 (9) (2019)
Jeremy H Pettus, David D'Alessio, Juan Pablo Frias, Eric G Vajda, James D Pipkin, Julio Rosenstock, Gretchen Williamson, Miriam A Zangmeister, Lin Zhi, Keith B Marschke
Efficacy and Safety of the Glucagon Receptor Antagonist RVT-1502 in Type 2 Diabetes Uncontrolled on Metformin Monotherapy: A 12-Week Dose-Ranging Study. Diabetes care 43 (1) (2019)
Emily D Parker, Eric T Wittbrodt, Jeffrey T McPheeters, Juan Pablo Frias
Comparison of healthcare resource utilization and costs in patients with type 2 diabetes initiating dapagliflozin versus sitagliptin. Diabetes, obesity & metabolism 21 (2) (2018)
Juan Pablo Frias, Elise Hardy, Azazuddin Ahmed, Peter Öhman, Serge A Jabbour, Hui Wang, Cristian Guja
Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION-8 randomized controlled trial. Diabetes, obesity & metabolism 20 (6) (2018)
Cristian Guja, Juan Pablo Frias, Aniko Somogyi, Serge A Jabbour, Hui Wang, Elise Hardy, Julio Rosenstock
Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION-7 randomized study. Diabetes, obesity & metabolism 20 (7) (2018)
Juan Pablo Frias, Manuel Puig Domingo, Stephen H Mandy, Raffaele Napoli, Minzhi Liu, Erika Soltes Rak, Vanita R Aroda
More patients reach glycaemic control with a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) than with basal insulin at 12 weeks of treatment: A post hoc time-to-control analysis of LixiLan-O and LixiLan-L. Diabetes, obesity & metabolism 20 (9) (2018)
Ronnie Aronson, Juan Pablo Frias, Allison Goldman, Amanda Darekar, Brett Lauring, Steven G Terra
Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study. Diabetes, obesity & metabolism 20 (6) (2018)
Serge A Jabbour, Juan Pablo Frias, Cristian Guja, Elise Hardy, Azazuddin Ahmed, Peter Öhman
Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study. Diabetes, obesity & metabolism 20 (6) (2018)
Juan Pablo Frias, Naunihal S Virdi, Praveen Raja, Yoona Kim, George Savage, Lars G Osterberg
Effectiveness of Digital Medicines to Improve Clinical Outcomes in Patients with Uncontrolled Hypertension and Type 2 Diabetes: Prospective, Open-Label, Cluster-Randomized Pilot Clinical Trial. Journal of medical Internet research 19 (7) (2017)